The generic version of Aldara is anticipated to be available after October 1, 2024. This timeline aligns with the expiration of Aldara's last patent, held on the Treatment for basal cell carcinoma
Aldara cream is used for the treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc). The efficacy of Aldara can be credited to imiquimod, its active ingredient, which operates by inducing interferon and other cytokines.
Aldara holds two patents, with the last one due to expire on October 1, 2024, unlocking the possibility of Aldara generic. This patent is for 'Treatment for basal cell carcinoma.' Below are the details of the patent: